Targeting epigenetic regulations in cancer

Acta Biochimica et Biophysica Sinica

Volumn 48, Issue 1, 2015, Pages 97-109

  Ning, Bo ^a   Li, Wenyuan ^a,b   Zhao, Wei ^a   Wang, Rongfu ^a,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b Central South University   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

anti cancer drugs; DNA methylation; epigenetic regulation; histone modification; inhibitors

Indexed keywords

CHROMATIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; HISTONE;

ACETYLATION; ANIMAL; CHROMATIN; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HISTONE CODE; HUMAN; METABOLISM; MOUSE; NEOPLASM; PROTEIN PROCESSING;

ACETYLATION; ANIMALS; CHROMATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE CODE; HISTONES; HUMANS; MICE; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC;

EID: 84954343740     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmv116     Document Type: Review

References (160)

1. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005, 45: 629-656.
2. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61: 3225-3229.
3. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37: 391-400.
4. Ning B, Liu G, Liu Y, Su X, Anderson GJ, Zheng X, Chang Y, et al. 5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. J Biol Chem 2011, 286: 37196-37206.
5. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6: 238-243.
6. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25: 84-90.
7. Adam J, Yang M, Soga T, Pollard PJ. Rare insights into cancer biology. Oncogene 2014, 33: 2547-2556.
8. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell 2014, 5: 265-296.
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128: 683-692.
10. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005, 6: 597-610.
11. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349: 2042-2054.
12. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007, 39: 457-466.
13. Bestor TH. Transposons reanimated in mice. Cell 2005, 122: 322-325.
14. Esteller M, Almouzni G. How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond. EMBO Rep 2005, 6: 624-628.
15. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4: 143-153.
16. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11: 726-734.
17. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007, 8: 286-298.
18. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3: 415-428.
19. Taylor C, Craven RA, Harnden P, Selby PJ, Banks RE. Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma. Int J Oncol 2012, 41: 1229-1240.
20. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009, 15: 7582-7592.
21. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92: 564-569.
22. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99: 247-257.
23. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984, 81: 6993-6997.
24. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005, 25: 4727-4741.
25. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10: 223-232.
26. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28: 605-613.
27. Creagan ET, Schaid DJ, Hartmann LC, Loprinzi CL. A phase II study of 5, 6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma. Am J Clin Oncol 1993, 16: 243-244.
28. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5: e9001.
29. Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106: 1794-1803.
30. Issa J-PJ, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103: 1635-1640.
31. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109: 52-57.
32. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27: 3842-3848.
33. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28: 556-561.
34. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007, 67: 6400-6408.
35. Lavelle D, Saunthararajah Y, Vaitkus K, Singh M, Banzon V, Phiasivongsva P, Redkar S, et al. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med 2010, 8: 92.
36. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324: 929-930.
37. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324: 930-935.
38. Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 2011, 25: 2436-2452.
39. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17: 637-641.
40. Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011, 9: 193-204.
41. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360: 2289-2301.
42. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41: 838-842.
43. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20: 11-24.
44. Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20: 25-38.
45. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366: 1079-1089.
46. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293: 1074-1080.
47. Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006, 98: 1443-1444.
48. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007, 128: 669-681.
49. Karpf AR, Matsui S-i. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 2005, 65: 8635-8639.
50. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996, 384: 641-643.
51. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, Anastasiadou E, et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005, 24: 368-381.
52. Huntly BJP, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6: 587-596.
53. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004, 23: 4225-4231.
54. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471: 189-195.
55. Cole PA. Chemical probes for histone-modifying enzymes. Nat Chem Biol 2008, 4: 590-597.
56. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325: 834-840.
57. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6: 38-51.
58. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4: 13-18.
59. Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol 2011, 2011: 475641.
60. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25: 3109-3115.
61. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27: 5410-5417.
62. Hu E, Dul E, Sung C-M, Chen Z, Kirkpatrick R, Zhang G-F, Johanson K, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003, 307: 720-728.
63. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget M-C, Kalita A, Liu J, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008, 7: 759-768.
64. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011, 12: 1222-1228.
65. Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 2010, 149: 518-528.
66. Guha M. HDAC inhibitors still need a home run, despite recent approval. Nat Rev Drug Discov 2015, 14: 225-226.
67. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, et al. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 2011, 17: 353-362.
68. Wang H, Yu N, Chen D, Lee KCL, Lye PL, Chang JWW, Deng W, et al. Discovery of (2E)-3-2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol- 5-yl-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem 2011, 54: 4694-4720.
69. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010, 9: 642-652.
70. Lai C-J, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang D-G, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010, 70: 3647-3656.
71. Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, Steggerda S, et al. PCI-24781, a novel hydroxamic acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol 2010, 2010: 207420.
72. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010, 5: e10941.
73. Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee J-H, Choi J, et al. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs 2012, 30: 1434-1442.
74. Chun S-M, Lee J-Y, Choi J, Lee J-H, Hwang JJ, Kim C-S, Suh Y-A, et al. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One 2015, 10: e0119379.
75. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002, 32: 606-613.
76. Network TCGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507: 315-322.
77. Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, et al. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis 2013, 4: e738.
78. Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 2010, 1: 117-136.
79. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, Wei G, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129: 823-837.
80. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009, 459: 108-112.
81. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011, 469: 343-349.
82. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42: 181-185.
83. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010, 107: 20980-20985.
84. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42: 722-726.
85. Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tönnissen ERLTM, van der Heijden A, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42: 665-667.
86. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20: 53-65.
87. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012, 3: 1288.
88. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RKM, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21: 1050-1063.
89. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492: 108-112.
90. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 2013, 12: 2113-2119.
91. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012, 8: 890-896.
92. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010, 18: 23-38.
93. Knutson SK, Warholic NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, et al. Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas. PLoS One 2014, 9: e111840.
94. Knutson SK, Warholic NM, Wigle TJ. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 2013, 110: 7922-7927.
95. Konze KD, Ma A, Li F, Barsyte-Lovejoy D. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 2013, 8: 1324-1334.
96. Chaib H, Nebbioso A, Prebet T, Castellano R, Garbit S, Restouin A, Vey N, et al. Anti-leukemia activity of chaetocin via death receptordependent apoptosis and dual modulation of the histone methyltransferase SUV39H1. Leukemia 2012, 26: 662-674.
97. Lai Y-S, Chen J-Y, Tsai H-J, Chen T-Y, Hung W-C. The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. Blood Cancer J 2015, 5: e313.
98. Lu Z, Tian Y, Salwen HR, Chlenski A, Godley LA, Raj JU, Yang Q. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. Anti-Cancer Drugs 2013, 24: 484-493.
99. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011, 7: 566-574.
100. Yuan Y, Wang Q, Paulk J, Kubicek S, Kemp MM, Adams DJ, Shamji AF, et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol 2012, 7: 1152-1157.
101. Rodriguez-Paredes M, Martinez de Paz A, Simó-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 2013, 33: 2807-2813.
102. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein H-U, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012, 18: 605-611.
103. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature 2013, 502: 480-488.
104. Chang K-H, King ONF, Tumber A, Woon ECY, Heightman TD, McDonough MA, Schofield CJ, et al. Inhibition of histone demethylases by 4-carboxy-2, 2'-bipyridyl compounds. ChemMedChem 2011, 6: 759-764.
105. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488: 404-408.
106. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 2014, 20: 1394-1396.
107. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114: 2733-2743.
108. Dubois S, Mareschal S, Cornic M, Picquenot J-M, Bertrand P, Bohers E, Maingonnat C, et al. Targeted EZH2 inhibitors in diffuse large B-cell lymphoma (DLBCL): immunohistochemical and mutational profiles of patients may determine candidates for treatment. ASH Annual Meeting and Exposition 2014, 124: 1656.
109. Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 2010, 79: 155-179.
110. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483: 603-607.
111. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21: 473-487.
112. Hayami S, Kelly JD, Cho H-S, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011, 128: 574-586.
113. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011, 50: 931-944.
114. Rose NR, Ng SS, Mecinović J, Liénard BMR, Bello SH, Sun Z, McDonough MA, et al. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem 2008, 51: 7053-7056.
115. Lohse B, Kristensen JL, Kristensen LH, Agger K, Helin K, Gajhede M, Clausen RP. Inhibitors of histone demethylases. Bioorg Med Chem 2011, 19: 3625-3636.
116. King ONF, Li XS, Sakurai M, Kawamura A, Rose NR, Ng SS, Quinn AM, et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One 2010, 5: e15535.
117. Liang Y, Vogel JL, Arbuckle JH, Rai G, Jadhav A, Simeonov A, Maloney DJ, et al. Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. Sci Transl Med 2013, 5: 167ra5.
118. Zhao W, Li Q, Ayers S, Gu Y, Shi Z, Zhu Q, Chen Y, et al. Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell 2013, 152: 1037-1050.
119. Zhao W, Ning B, Qian C. Regulatory factors of induced pluripotency: current status. Stem Cell Investigation 2014, 1: 7.
120. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell Res 2007, 17: 850-857.
121. Heinemann B, Nielsen JM, Hudlebusch HR, Lees MJ, Larsen DV, Boesen T, Labelle M, et al. Inhibition of demethylases by GSK-J1/J4. Nature 2014, 514: E1-E2.
122. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482: 226-231.
123. Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340: 857-861.
124. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007, 13: 3682-3688.
125. Hirota T, Lipp JJ, Toh B-H, Peters J-M. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 2005, 438: 1176-1180.
126. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4: 927-936.
127. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009, 2009: 636-642.
128. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in myelofibrosis. N Engl J Med 2010, 363: 1117-1127.
129. Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs 2010, 19: 427-436.
130. Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011, 25: 1751-1759.
131. Ismail IH, McDonald D, Strickfaden H, Xu Z, Hendzel MJ. A small molecule inhibitor of Polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. J Biol Chem 2013, 288: 26944-26954.
132. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatinbinding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007, 14: 1025-1040.
133. Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PWTC, Bauer C, Münzel M, et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 2013, 152: 1146-1159.
134. Lan F, Collins RE, De Cegli R, Alpatov R, Horton JR, Shi X, Gozani O, et al. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 2007, 448: 718-722.
135. Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448: 714-717.
136. Peña PV, Davrazou F, Shi X, Walter KL, Verkhusha VV, Gozani O, Zhao R, et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 2006, 442: 100-103.
137. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399: 491-496.
138. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007, 8: 983-994.
139. Chi P, Allis CD, Wang GG. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10: 457-469.
140. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan W-I, Robson SC, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478: 529-533.
141. Chung C-w, Dean AW, Woolven JM, Bamborough P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem 2012, 55: 576-586.
142. Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway RC, Kornberg RD. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci USA 1998, 95: 8538-8543.
143. Malik S, Roeder RG. The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet 2010, 11: 761-772.
144. Yang Z, Yik JHN, Chen R, He N, Jang MK, Ozato K, Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005, 19: 535-545.
145. Shang E, Wang X, Wen D, Greenberg DA, Wolgemuth DJ. Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Dev Dyn 2009, 238: 908-917.
146. Houzelstein D, Bullock SL, Lynch DE, Grigorieva EF, Wilson VA, Beddington RSP. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol Cell Biol 2002, 22: 3794-3802.
147. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, et al. Selective inhibition of BET bromodomains. Nature 2010, 468: 1067-1073.
148. Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 2015, 348: 1376-1381.
149. Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014, 123: 697-705.
150. Pastori C, Kapranov P, Penas C, Peschansky V, Volmar C-H, Sarkaria JN, Bregy A, et al. The bromodomain protein BRD4 controlsHOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci USA 2015, 112: 8326-8331.
151. Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C, Ingerman LA, et al. Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 2011, 54: 2504-2511.
152. James LI, Korboukh VK, Krichevsky L, Baughman BM, Herold JM, Norris JL, Jin J, et al. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J Med Chem 2013, 56: 7358-7371.
153. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014, 510: 278-282.
154. Herold JM, Ingerman LA, Gao C, Frye SV.Drug discovery toward antagonists of methyl-lysine binding proteins. Curr Chem Genomics 2011, 5: 51-61.
155. Lu R, Wang GG. Tudor: a versatile family of histone methylation 'readers'. Trends Biochem Sci 2013, 38: 546-555.
156. Chen C, Nott TJ, Jin J, Pawson T. Deciphering arginine methylation: Tudor tells the tale. Nat Rev Mol Cell Biol 2011, 12: 629-642.
157. Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Börno ST, Fälth M, Kuner R, et al. ERG induces epigenetic activation of Tudor domaincontaining protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One 2013, 8: e59976.
158. Gurvich N, Perna F, Farina A, Voza F, Menendez S, Hurwitz J, Nimer SD. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci USA 2010, 107: 22552-22557.
159. James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, MacNevin CJ, et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 2013, 9: 184-191.
160. Campbell RM, Tummino PJ. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 2014, 124: 64-69.